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OBJECTIVES We tested the hypothesis that the response to flecainide infusion can identify patients with
atrial fibrillation (AF) in whom the hybrid pharmacologic and ablation therapy reduces the
recurrences of AF.
BACKGROUND Infusion of class IC anti-arrhythmic drugs may promote transformation of AF into atrial
flutter. Catheter ablation of atrial flutter has been demonstrated to be highly effective in
preventing recurrences of atrial flutter.
METHODS Seventy-one consecutive patients with paroxysmal or chronic AF, in whom flecainide infusion
(2 mg/kg body weight, intravenously) determined the transformation of AF into common
atrial flutter (positive response), were randomized to receive one of the following treatments:
oral pharmacologic treatment with flecainide (group A, n 5 23); the hybrid treatment
(catheter ablation of the inferior vena cava-tricuspid annulus isthmus, plus oral flecainide)
(group B, n 5 24); or catheter ablation of the isthmus only (group C, n 5 24). Thirty-seven
patients with a negative response to flecainide, who chose to be submitted to the hybrid
treatment, were selected as the control group (group D).
RESULTS During a mean follow-up period of 24 6 7.2 months, the recurrences of AF and atrial flutter
in group B (42%) were significantly lower than those in group A (78%, p , 0.001), group C
(92%, p , 0.001) and group D (92%, p , 0.001).
CONCLUSIONS The creation of a complete bi-directional conduction block at the inferior vena cava-tricuspid
annulus isthmus, plus flecainide administration, reduces the recurrences of both AF and atrial
flutter in patients with class IC atrial flutter. Moreover, the early response to flecainide is safe
and reliable in identifying patients who may benefit from this therapy. (J Am Coll Cardiol
2001;37:1639–44) © 2001 by the American College of Cardiology
Atrial fibrillation (AF) and atrial flutter, both intra-atrial
re-entrant tachycardia with different electrophysiologic
mechanisms, are frequently associated in an individual
patient. Spontaneous and pharmacologic transformation of
AF into atrial flutter has been well documented (1,2).
Recently, it has been reported that radiofrequency ablation
of the inferior vena cava-tricuspid annulus isthmus in
patients developing atrial flutter while receiving oral class IC
anti-arrhythmic drug therapy (class IC atrial flutter) for AF,
reduces the number of AF recurrences (3–5). The aim of
this study was to test the hypothesis that the response to
flecainide infusion can identify patients in whom the hybrid
pharmacologic and ablation therapy reduces the recurrences
of AF.
METHODS
Patient selection and study protocol. Between March
1997 and January 1999, 71 of 404 patients referred to our
centers for electrophysiologic evaluation of AF were en-
rolled. The inclusion criterion was drug-refractory paroxys-
mal or chronic AF with persistent, typical atrial flutter
conversion during flecainide infusion (10 min) at the dose of
2 mg/kg body weight intravenously (positive test response)
(Fig. 1). Exclusion criteria were: 1) a history of sick sinus
syndrome or pause $2.5 s during 24-h electrocardiographic
(ECG) Holter recording; 2) a tri-fascicular block or any
degree of atrioventricular block; 3) an implantable pacing
device; 4) a history of a sustained ventricular arrhythmia,
cardiac arrest or congenital long QT syndrome; 5) a history
of myocardial infarction or a revascularization procedure
within the previous 6 months; and 6) signs of severe cardiac
or respiratory insufficiency with a left ventricle ejection
fraction ,40%. Patients enrolled were randomized to re-
ceive one of three different therapeutic approaches: 1)
long-term oral pharmacologic treatment with 200 mg/day
of flecainide (group A); 2) catheter ablation of the inferior
vena cava-tricuspid annulus isthmus, plus long-term oral
pharmacologic treatment with 200 mg of flecainide (the
hybrid approach; group B); or 3) catheter ablation of the
isthmus only (group C). A group of 37 patients in whom the
infusion of flecainide failed to convert AF into atrial flutter
(negative test response), who chose to be submitted to the
hybrid approach as the first step of a procedure of atria
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compartmentalization, was selected as the control group. All
patients were followed up for at least 15 months (mean
24 6 7.2), with a clinical examination and ECG recording
scheduled every month. Patients were instructed to obtain
an ECG record in case of symptomatic palpitation. During
the follow-up, patients received no other anti-arrhythmic
drug except flecainide, nor drugs affecting the atrioventric-
ular node conduction (digoxin, beta-blockers and calcium
channel blockers), so that the patient’s capacity to recognize
arrhythmia recurrences would not be diminished.
The study was approved by the Ethics Committee of our
institutions, and all patients gave their informed consent to
participate in the study.
Definitions. Typical atrial flutter was defined as atrial
flutter exhibiting a counterclockwise or clockwise activation
around the tricuspid annulus, with a proximal to distal
coronary sinus depolarization, as well as concealed entrain-
ment demonstrated at annular pacing sites within the
tricuspid valve-eustachian ridge isthmus, with a post-pacing
interval similar to the flutter cycle length (6,7). Atypical
atrial flutter was defined as all other flutters in which
participation of the isthmus in the circuit was excluded by
the aforementioned criteria.
Electrophysiologic study and radiofrequency ablation.
All patients underwent electrophysiologic study and cathe-
ter ablation in a single session, while in the fasting state,
after discontinuation of all anti-arrhythmic therapies for at
least five half-lives. Two decapolar electrode catheters or a
halo catheter with 20 electrodes were placed around the
tricuspid annulus to assess the activation sequence in the
lateral wall; two quadripolar electrode catheters were placed
in the coronary sinus, with the proximal electrode pair
located at the ostium, and in the His bundle area, respec-
tively. A 7F, thermistor, quadripolar electrode catheter (EP
Technology, Mountain View, California), with an 8- or
10-mm deflectable tip, was used to stimulate and ablate. All
patients were in stable AF at the time of the flecainide test.
Once completed, the patients who had flecainide infusion
were observed for at least 20 min, during which time they
had no further drug infusion. If AF was converted into
stable, common atrial flutter, the patients underwent radio-
frequency catheter ablation. The method of ablation was
anatomic: a line of sequential overlapping lesions was given
during pullback of the ablation catheter from the tricuspid
valve annulus toward the inferior vena cava-eustachian
ridge. Radiofrequency energy was delivered by a generator
(EPT 1000XP, EP Technology) to achieve a tip-tissue
interface temperature of 65°C and an output of up to
150 W. Successful ablation was defined as interruption of
the atrial flutter, achievement of bi-directional isthmus
conduction block and no induction of persistent, common
atrial flutter (8). Complete isthmus block was defined by the
co-existence of a counterclockwise conduction to the point
of block, followed by the delayed arrival of septal activation
up to the line of block from the opposite direction, during
low lateral right atrium pacing, and a similar activation
pattern in the opposite direction, during proximal coronary
sinus pacing (9,10).
Statistical analysis. Continuous variables are expressed as
the mean 6 SD and were compared using the two-tailed
Student t test or the exact Fisher test for proportional
comparisons. Analysis of variance, with Bonferroni and
Tukey post hoc multiple comparison tests, was performed to
make comparisons among multiple groups. For categorical
data, Bonferroni correction was applied. The Cox propor-
tional hazards model was used to assess the relationship
between explanatory variables and event-free survival times.
The log-rank test was used to compare the Kaplan-Meier
event-free survival curves in the four groups.
RESULTS
Patients characteristics. Table 1 summarizes the clinical
characteristics of the patients with positive and negative test
responses. The incidence of at least one episode of docu-
mented atrial flutter occurring before the flecainide test was
significantly higher in the group with a positive test re-
sponse than in the group with a negative test response (39%
vs. 15%, p , 0.001). As shown in Table 2, there was no
significant difference in any of the clinical characteristics
between the three study groups and the control group,
excluding, once again, the incidence of pre-test atrial flutter,
which was significantly lower in group D than in group A
(p , 0.05). Among the 108 patients of groups A, B, C and
D, 49 (7 in group A, 6 in group B, 7 in group C and 29 in
group D) received anti-coagulation therapy with warfarin,
whereas the remaining 59 patients received anti-aggregant
therapy with acetylsalicylic acid, indobufene or ticlopidine.
During the follow-up, one patient in group D had a
nonfatal stroke.
Flecainide test response and ablation catheter outcome.
During flecainide infusion, sinus rhythm was restored in
four patients, all with paroxysmal AF, and they were
included in the group with a negative test response; two
other patients in whom sinus rhythm restoration was
preceded by a stable period (5 and 12 min, respectively) of
typical atrial flutter were enrolled in the group with a
positive test response. In the group with a positive test
response, 1:1 atrioventricular conduction was observed in 9
(12.6%) of 71 patients, resulting in hemodynamic detriment
in one of them, which required atrial overdrive pacing to
convert the atrial flutter into sinus rhythm; in four other
patients (5.6%), a transient bundle brunch block was ob-
served, one of whom had first-degree atrioventricular block
after restoration of sinus rhythm. Among the patients who
showed 1:1 atrioventricular conduction during the flecainide
Abbreviations and Acronyms
AF 5 atrial fibrillation
ECG 5 electrocardiographic
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Figure 1. Surface intracardiac electrograms recorded before (A) and after (B) flecainide infusion, showing the transformation of atrial fibrillation into typical
atrial flutter. I, III and V1 5 electrocardiographic leads; CS 5 coronary sinus; HIS 5 His bundle; -d 5 distal; -p 5 proximal; T 5 tricuspid annulus, with
T12 located at the low lateral atrium and T1516 at the high inter-atrial septum.
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test, three were randomized into group A, four into group B
and four into group C. During the follow-up, only one
patient in group A experienced atrial flutter with 1:1
atrioventricular conduction, with a mean atrial flutter cycle
of 420 ms, with no hemodynamic compromise. The mean
atrial flutter cycle was 238 6 33 ms; surface ECG moni-
toring and intracardiac mapping revealed that 64 (90%) of
71 patients had counterclockwise typical atrial flutter, and 7
(10%) of 71 patients had clockwise typical atrial flutter. In
the group with a negative test response, a transient bundle
brunch block was observed in 12 patients (3.6%); in 29 other
patients (8.7%), transient (n 5 16) or persistent (n 5 13)
atypical atrial flutter was observed. Among this latter group,
two patients showed a phase of 1:1 atrioventricular conduc-
tion.
A complete bi-directional isthmus conduction block was
obtained in all patients in groups B, C and D, with a mean
number of 7.8 6 4.5 pulses of radiofrequency energy; in two
patients, a second procedure was required to achieve a
complete isthmus block. The mean procedure time was
32 6 6 min, with a mean X-ray time of 17 6 5 min. No
major complications were observed during and after the
isthmus ablation. During the follow-up, four patients (one
in group A, one in group B and two in the control group)
were excluded because of pharmacologic side effects: one
patient had central nervous system adverse reactions, with
blurred vision and headache; one patient showed a first-
degree atrioventricular block; and two patients had effort
dyspnea due to hemodynamic compromise.
Recurrences of AF. Atrial fibrillation- and atrial flutter-
free survival curves are shown in Figure 2. Log-rank test
comparisons resulted in a significant difference between the
curves of group B and those of groups A, C and D
(chi-square 9.6, p , 0.002; chi-square 21.1, p , 0.001; and
chi-square 18.2, p , 0.001, respectively). No significant
differences were found between the curves of groups A, C
and D. All patients in groups A, B, C and D had AF
recurrences, except for one patient in group A who experi-
enced atrial flutter recurrence. After the first arrhythmia
recurrence, 17 of 18 patients in group A underwent isthmus
ablation; all patients in group C began long-term oral
pharmacologic treatment with 200 mg of flecainide; and 9
of 10 patients in group B required electrical cardioversion to
restore sinus rhythm.
Age, gender, left atrial diameter, left ventricle ejection
fraction, paroxysmal or chronic AF, the presence of heart
disease, a history of atrial flutter and therapeutic modalities
(group A, B, C or D) were considered as explanatory
variables in the Cox proportional hazards model. Only the
therapeutic modalities variable was retained in the final
model after stepwise selection, and, in particular, the coding
for only group B reached statistical significance, confirming
Table 1. Clinical Characteristics of the Patients With Positive and Negative Test Responses
Positive Test
Response
(n 5 71)
Negative Test
Response
(n 5 333) p Value
Age (years) 53.3 6 13 54.4 6 13 0.53
Gender (M/F) 47/24 207/126 0.52
LVEF (%) 52.5 6 8.6 53.7 6 7.4 0.26
LA diameter (mm) 41.3 6 4.7 42.2 6 4.8 0.15
Clinical arrhythmia (PAF/CAF) 49/22 239/94 0.65
Heart disease 43 (60.5%) 242 (72.7%) 0.78
Hypertension 27 (38%) 147 (44.2%) 0.8
Valvular 10 (14.1%) 66 (19.8%) 0.58
Ischemic 6 (8.4%) 29 (8.7%) 0.72
Pre-test AFL 28 (39.4%) 49 (14.7%) , 0.001
Data are presented as the mean value 6 SD or number of patients.
AFL 5 atrial flutter; CAF 5 chronic atrial fibrillation; F 5 female; LA 5 left atrium; LVEF 5 left ventricular ejection
fraction; M 5 male; PAF 5 paroxysmal atrial fibrillation.
Table 2. Clinical Characteristics of the Four Study Groups
Group A
(n 5 23)
Group B
(n 5 24)
Group C
(n 5 24)
Group D
(n 5 37)
Age (years) 54 6 12 53 6 13 52 6 14 54 6 14
Gender (M/F) 17/6 16/8 14/10 25/11
LVEF (%) 52 6 9 52 6 9 53 6 9 54 6 6
LA diameter (mm) 41 6 4 41 6 5 41 6 5 43 6 5
Clinical arrhythmia (PAF/CAF) 16/7 16/8 17/7 21/16
Heart disease 14 (60.8%) 14 (58.3%) 15 (62.5%) 30 (81%)
Hypertension 9 (39.1%) 9 (37.5%) 9 (37.5%) 16 (43.2%)
Valvular 3 (13%) 4 (16.7%) 3 (12.5%) 9 (24.3%)
Ischemic 2 (8.7%) 1 (4.1%) 3 (12.5%) 5 (13.5%)
Pre-test AFL 10 (43.5%) 9 (37.5%) 9 (37.5%) 4 (10.8%)
Data are presented as the mean value 6 SD or number (%) of patients.
Abbreviations as in Table 1.
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that the event-free survival curve of patients with a positive
response to flecainide administration and the hybrid therapy
was different from the curves of all of the other groups.
Considering only the patients receiving the hybrid therapy,
after 15 months of follow-up, 58% of the patients with a
positive flecainide test were free of AF and atrial flutter
recurrence, whereas only 8% of the patients with a negative
test did not experience a new episode of AF or atrial flutter.
DISCUSSION
To our knowledge, this is the first study to demonstrate, in
a prospective, randomized fashion, the efficacy of the hybrid
therapy, inferior vena cava-tricuspid annulus ablation, plus
anti-arrhythmic drug administration, in the treatment of
class IC atrial flutter. Moreover, validation of the flecainide
infusion test, as a predictor of long-term success, might
facilitate the selection of patients who are candidates for this
approach.
Conversion of AF into atrial flutter. Atrial fibrillation
and atrial flutter are re-entrant atrial arrhythmias involving
multiple re-entrant wave fronts in the case of AF and a
single macro-re-entrant wave front in the case of atrial
flutter. In the canine model (11), the spontaneous transfor-
mation of AF into atrial flutter was related to the develop-
ment of a line of functional block, of critical length, along
the right free wall; the occurrence of this phenomenon was
enhanced by the administration of class I anti-arrhythmic
drugs. In humans, a brief period of irregular atrial activity in
one or more intracardiac leads was observed in most of the
study patients with inducible atrial flutter during pro-
grammed atrial stimulation (12). In patients after open heart
surgery, Waldo and Cooper (13) reported the presence of a
transitional rhythm, usually AF, preceding the spontaneous
onset of atrial flutter. Recently, a mapping study (1),
performed with multi-electrode recordings, stressed the role
of excitability of the narrow isthmus between the inferior
vena cava and the tricuspid annulus as crucial for the
organization of AF into atrial flutter. Class I anti-
arrhythmic drugs may predispose to the development of
atrial flutter by depressing conduction velocity to a greater
extent than they prolong the atrial refractory period, result-
ing in a decrease in the atrial wavelength. In our study, early
infusion of flecainide promoted the transformation of AF
into atrial flutter in 17.5% of patients, a value slightly
superior to that (11% to 12.8%) of patients with AF
developing atrial flutter during oral therapy with class IC
anti-arrhythmic drugs (5,14). The difference might be due
to the pharmacokinetics of the intravenous infusion and the
dosage used, which, in our study, was adjusted to the
patients’ weight. Moreover, 77 (19%) of 404 patients had at
least one documented pre-test episode of typical atrial
flutter. In our study, this variable was the only clinical
characteristic that predicted the response to flecainide (pos-
itive in 36.4% of patients with pre-test atrial flutter vs.
13.1% of patients without pre-test atrial flutter; p , 0.001).
Effects of combined ablation and drug therapy on AF
recurrences. The conversion of AF into atrial flutter by
anti-arrhythmic drugs, as well as the observation of atrial
flutter in patients with untreated AF, with periodic transi-
tion from one arrhythmia to the other, suggesting a caus-
ative relationship between AF and atrial flutter, led some
investigators (3–5,14–16) to propose the hybrid pharmaco-
logic and ablation therapy for the treatment of patients with
AF developing atrial flutter during anti-arrhythmic drug
therapy. In these small, noncontrolled series, the long-term
success rate of the hybrid therapy ranged widely from 36.8%
to 93%. In our study of patients with a positive response to
flecainide, the hybrid therapy was significantly superior to
the anti-arrhythmic drug therapy and the ablation therapy
alone, in reducing the recurrences of both AF and atrial
flutter (58.3% vs. 21.7% vs. 8.3% of patients were symptom
free in the three respective groups). For the first time, we
report that the efficacy of the hybrid therapy was confined to
patients with a positive test (only 8.1% of patients with a
negative response were symptom-free at late follow-up),
leading to the conclusion that the response to flecainide
infusion is reliable in detecting patients who could benefit
from the hybrid therapy.
Study limitations. The study has several potential limita-
tions: 1) the efficacy of the therapy was assessed on the basis
of the patients’ symptoms; however, brief episodes of atrial
arrhythmias may be asymptomatic. 2) The results of this
study might be of limited clinical value in countries in which
the intravenous form of flecainide is not available. However,
these results should impel the introduction of this modality
of drug administration. Naturally, it should be investigated
whether similar results can be achieved with other class IC
anti-arrhythmic drugs, like propafenone. 3) Although a
positive flecainide test was a significant predictor of the
long-term success of the hybrid therapy, the test was far
from being an accurate predictor (42% of patients with a
positive flecainide test had recurrent arrhythmias during the
hybrid therapy). It is obvious that the response to a single
intravenous dose of flecainide may not reflect what happens
during long-term oral therapy. However, the safety and
reliability of the test, as well as isthmus ablation, should
Figure 2. Atrial fibrillation- and atrial flutter-free cumulative survival
curves for the four patient groups (A–D).
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encourage this approach, instead of performing isthmus
ablation alone, in patients with stable atrial flutter during
long-term oral flecainide therapy.
Clinical implications. The results of our study suggest that
the hybrid therapy is effective in preventing both AF and
atrial flutter recurrences in ;60% of patients with class IC
atrial flutter. Moreover, the response to flecainide infusion is
safe and reliable in identifying patients who may benefit
from this therapy. The routine use of the flecainide test in
the electrophysiology laboratory, to study patients with AF,
might widen the percentage of patients who are candidates
for the hybrid therapy.
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